Stockreport

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection

Quanterix Corporation  (QTRX) 
US:NASDAQ Investor Relations: ir.quanterix.com/investor-relations
PDF Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix’s LucentAD® Complete LDT BILLERICA, Mass.--(BUSINESS WIRE)- [Read more]